Stephane L Bogen

Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.

Zhuyan Guo, Frank Bennett, Rong-Sheng Yang, 2007, Journal of medicinal chemistry.

Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor.

Weiying Yang, Frank Bennett, Jesse Wong, 2010, ACS medicinal chemistry letters.

Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.

Frank Bennett, X. Tong, A. Arasappan, 2009, Journal of medicinal chemistry.

The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir: a change in direction in the search for a second generation HCV NS3 protease inhibitor.

Zhuyan Guo, Frank Bennett, X. Tong, 2010, Bioorganic & medicinal chemistry letters.

Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.

Weiying Yang, Frank Bennett, X. Tong, 2009, Journal of medicinal chemistry.